Imperative Care Announces First-In-Human Study of Novel Implant Designed to Enable Single Antiplatelet Therapy After Aneurysm Treatment

Imperative Care Announces First-In-Human Study of Novel Implant Designed to Enable Single Antiplatelet Therapy After Aneurysm Treatment




Imperative Care Announces First-In-Human Study of Novel Implant Designed to Enable Single Antiplatelet Therapy After Aneurysm Treatment

First patients treated with investigational Neurovascular Stent System by Dr. Nobuyuki Sakai at Kobe City Medical Center General Hospital, Japan

Low-profile, coated stent with potential applications that could allow patients to avoid complications of dual antiplatelet therapy

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initiation of a first-in-human clinical study for its novel stent system designed to only require single antiplatelet therapy for patients undergoing stent-assisted treatment of wide-neck intracranial aneurysms.


The first three patients enrolled were successfully treated by Dr. Nobuyuki Sakai, Director of Neurosurgery at the Kobe City Medical Center General Hospital in Kobe City, Hyogo, Japan. All three patients underwent planned procedures for stent-assisted coiling of unruptured aneurysms, and all three were discharged from the hospital within 48 hours on an aspirin-only antiplatelet regimen and without any device or procedure-related complications – including clot formation.

The ability for neurovascular implants to avoid dual antiplatelet drug therapy, which carries the risk of serious bleeding complications, will be an important step forward,” said Dr. Sakai. “I am encouraged by these positive early results with Imperative Care’s innovative stent technology and look forward to future investigations in a wide range of patients, including those with ruptured aneurysms.”

The company’s investigational stent system is a coated, extremely low-profile nitinol scaffold designed as a platform technology for a range of vascular applications. The initial focus of the company’s clinical development program is neurovascular disorders, beginning with wide-neck aneurysms. The company intends to investigate versions of the stent for a wider scope of hemorrhagic and ischemic stroke-related conditions.

A single antiplatelet stent, which is designed to allow patients to be managed solely on aspirin, will be a game-changer for patient outcomes and in the practice of neurointerventional surgery,” said Aquilla Turk, D.O., Imperative Care’s Chief Medical Officer and practicing neuroendovascular surgeon at Greenville Health System in South Carolina.

By aiming to eliminate the tradeoff between the risk of clot formation without dual antiplatelet therapy and bleeding complications with antiplatelet therapy, the Imperative Care stent could represent a platform technology with improved safety and broad applications in neurovascular disorders beyond unruptured aneurysms,” added Dr. Turk.

We are pleased with the progress to date with our neurovascular stent, which combines a hemodynamically-optimized nitinol architecture with a proprietary coating that naturally resists clot formation,” said Fred Khosravi, Chairman and CEO of Imperative Care. “There is a great deal more work to be done to bring a single antiplatelet stent to patients, but we are deeply committed to making this innovative and critically important technology a major force in future neurovascular treatments. In addition to the neurovascular applications, we believe that a single antiplatelet stent could make an important contribution in other targets within the vascular system.”

About Imperative Care, Inc.

Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

*The Neurovascular Stent System described herein is not approved or available for sale.

Contacts

Investor Contact:
Matt Garrett, CFO

Imperative Care, Inc.

408-476-1672

mgarrett@imperativecare.com

Media Contact:

Lara Lingenbrink

Imperative Care, Inc.

858-525-1414

llingenbrink@imperativecare.com